Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dolutegravir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 18/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dolutegravir SCHEMBL16478545 | 1.00 | SLC22A2 (1.00) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Dolutegravir SCHEMBL29474777 | 1.00 | SLC22A2 (1.00) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Dolutegravir SCHEMBL12264130 | 1.00 | SLC22A2 (1.00) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Dolutegravir SCHEMBL19929649 | 1.00 | SLC22A2 (1.00) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Dolutegravir SCHEMBL16440360 | 1.00 | SLC22A2 (1.00) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Dolutegravir SCHEMBL16440366 | 1.00 | SLC22A2 (1.00) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Dolutegravir SCHEMBL80619 | 1.00 | SLC22A2 (1.00) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Dolutegravir SCHEMBL29357473 | 1.00 | SLC22A2 (1.00) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Dolutegravir SCHEMBL10346729 | 1.00 | SLC22A2 (1.00) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Dolutegravir SCHEMBL1835959 | 0.99 | SLC22A2 (0.98) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | GILEAD SCIENCES, INC. (US) | 2026-04-28 | — | — | US | claimed |
| US-12227518-B2 | Crystalline polymorphs of sodium (4R,12AS)-9-{[(2,4-difluorophenyl) methyl]carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12A-hexahydro-2H-pyrido [1′,2′:4,5]pyrazino[2,1-b][1,3]oxazin-7-olate and process for preparation thereof | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2025-02-18 | — | — | US | claimed |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | claimed |
| WO-2023091964-A2 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF TUMOR METASTASIS AND HORIZONTAL GENE TRANSFER | THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (US) | 2023-05-25 | — | — | WO | claimed |
| EP-4140485-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2023-03-01 | — | — | EP | claimed |
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | claimed |
| EP-3166607-B1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2022-08-31 | — | — | EP | claimed |
| US-20220218711-A1 | COMBINATION OF A TLR7 MODULATING COMPOUND AND AN HIV VACCINE | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | claimed |
| EP-3972640-A1 | COMBINATION OF A TLR7 MODULATING COMPOUND AND AN HIV VACCINE | GILEAD SCIENCES, INC. (US) | 2022-03-30 | — | — | EP | claimed |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2022-03-03 | — | — | US | claimed |
| US-20170224695-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | claimed |
| US-20170224694-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | claimed |
| US-20170209454-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-07-27 | — | — | US | claimed |
| EP-3187226-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV Healthcare Company (US) | 2017-07-05 | — | — | EP | claimed |
| US-8129385-B2 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | claimed |
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122055369-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2010011812-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011819-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | VIIV HEALTHCARE COMPANY | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209454-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | SLC22A2 2974/4885CYP3A4 28/4885TMEM97 3548/4885 |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | IRF3, STING1, MAVS | SLC22A2 3484/4885CYP3A4 3581/4885TMEM97 2497/4885 |
| US-20170224694-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | SLC22A2 2974/4885CYP3A4 28/4885TMEM97 3548/4885 |
| US-20220218711-A1 | COMBINATION OF A TLR7 MODULATING COMPOUND AND AN HIV VACCINE | TLR7, TLR3, TLR9 | SLC22A2 4131/4885CYP3A4 3239/4885TMEM97 2081/4885 |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | SLC22A2 1927/4885CYP3A4 2399/4885TMEM97 122/4885 |
| US-12227518-B2 | Crystalline polymorphs of sodium (4R,12AS)-9-{[(2,4-difluorophenyl) methyl]carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12A-hexahydro-2H-pyrido [1′,2′:4,5]pyrazino[2,1-b][1,3]oxazin-7-olate and process for preparation thereof | CYP4A11, CYP4B1, CYP4F11 | SLC22A2 1302/4885CYP3A4 22/4885TMEM97 3336/4885 |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | SLC22A2 1927/4885CYP3A4 2399/4885TMEM97 122/4885 |
| US-20170224695-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NCOA4, NR4A1, NR4A2 | SLC22A2 3012/4885CYP3A4 26/4885TMEM97 3407/4885 |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | NR4A1, NCOA4, NR4A2 | SLC22A2 2976/4885CYP3A4 28/4885TMEM97 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.